Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 472

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 472
---
 stock held directly by Mr. Giacobello; (ii) 443,345 shares issuable                                                                        
 upon the exercise of options within 60 days of December 31, 2024; and (iii) 6,750 shares issuable upon the vesting of restricted stock units within 60 days of December 31, 2024. |

| (9) | Consists of (i) 100,000 shares to be purchased in the PIPE Offering; (i) 100,000 shares of common stock held 
 directly by Mr. Ball; (ii) 192,996 shares of common stock issuable upon the exercise of options within       |

- 319 -

| 60 days of December 31, 2024 and (iii); 5,000 shares issuable upon the vesting of restricted stock units within 60 days of December 31, 2024. |

| (10) | Consists of (i) 1,171,543 shares of common stock held indirectly by the Anishka Family Trust, (ii) 639,698                                                                                                                              
 shares of common stock held indirectly by the Anishka Irrevocable 2016 Trust dated October 19, 2016 (the “Anishka Irrevocable Trust”), and (iii) 455,450 shares of common stock issuable upon the exercise of options within 60 days of 
 December 31, 2024. Dr. Desai disclaims beneficial ownership of the securities held in the Anishka Irrevocable Trust, except to the extent of any pecuniary interest therein.                                                            |

| (11) | Consists of (i) 346,226 shares of common stock issuable upon the exercise of options within 60 days of                                                                                                   
 December 31, 2024 (ii); 7,500 shares issuable upon the vesting of restricted stock units within 60 days of December 31, 2024and (iii) 3,000 shares of common stock held indirectly by Dr. Itri’s spouse. |

| (12) | Consists of (i) 1,666,000 shares to be purchased in the PIPE Offering by KVP Capital, LP (“KVP                                                                                                                                           
 Capital”); (ii) 19,694 shares of common stock held directly by Dr. Castelein, (iii) 499,998 shares of common stock held indirectly by KVP Capital, LP (“KVP